Ex vivo thrombin generation in patients with venous thromboembolic disease or atrial fibrillation on long-term oral anticoagulation.
International normalized ratio (INR) is used to monitor chronic oral anticoagulant (OA) treatment; however, it is poorly understood how this simple test reflects in vivo hemostatic reactions, culminating in thrombin generation and clot formation. We studied the process of thrombin generation using an ex vivo model, where thrombin-antithrombin (TAT) complexes are measured in blood emerging from standardized skin incisions in 55 patients (35 with venous thromboembolism [VTE] and 20 with sustained atrial fibrillation [AF]) treated with acenocoumarol (INR 2.0-3.0). In addition, in venous blood, we measured the activity of factor VIII (FVIII) and vitamin K-dependent coagulation proteins. Chronic anticoagulation led to significant reductions in maximum TAT concentrations as compared to 35 healthy controls, in maximum TAT generation rates, and in mean amount of thrombin generated. Parameters of thrombin generation did not correlate with INR or any coagulation factor measured. International normalized ratio was significantly and independently affected by the decrease in the activity of all vitamin K-dependent coagulation proteins. The strongest influence was shown for FVII. Factor VIII activity was increased in all patients studied independently of the duration of anticoagulation and did not change over time. In conclusion, in patients with VTE and AF on OA, there is no correlation between INR values and parameters of ex vivo thrombin generation. This may indicate an important role of protein C (PC) system and possibly other endothelium-dependent mechanisms in controlling hemostasis. Increased FVIII activity in patients with VTE and AF does not change significantly during anticoagulation and is probably related to the pretreatment prothrombotic state.
Musial
Jacek
J
Department of Medicine, Jagiellonian University Medical College, Krakow, Poland. mmmusia@cyf-kr.edu.pl
Brzezinska-Kolarz
B
B
Zólcinski
M
M
Lelakowski
J
J
Szczeklik
A
A
D000074:Acenocoumarol / Q000008:administration & dosage*; D000925:Anticoagulants / Q000008:administration & dosage*; D000991:Antithrombins / Q000378:metabolism; D001281:Atrial Fibrillation / Q000097:blood* / Q000188:drug therapy*; D016022:Case-Control Studies; D005169:Factor VIII / Q000378:metabolism; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011516:Prothrombin / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism*; D054556:Venous Thromboembolism / Q000097:blood* / Q000188:drug therapy*
D000925:Anticoagulants; D000991:Antithrombins; D011516:Prothrombin; D005169:Factor VIII; D013917:Thrombin; D000074:Acenocoumarol